Clinical Trial Update: Diva - The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the effects of 12 weeks of high-dose valsartan (320 mg) added to amlodipine on endothelial function in hypertensive subjects wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Metabolic Syndrome

Drugs mentioned

• DIOVAN (valsartan)
• NORVASC (amlodipine besylate)

Snippet

Sponsor: Novartis | Conditions: Hypertension, Metabolic Syndrome | Phase 4 | Status: COMPLETED